Mode
Text Size
Log in / Sign up
N/A N=10 Treatment

PEEP Mask for Tracheobronchomalacia-Induced Cough

Tracheobronchomalacia

Enrolled (actual)
10
Serious AEs
0.0%
Results posted
Sep 2023
Primary outcome: Primary: Change in Cough Severity as Measured by the Cough Visual Analog Scale (VAS) — -50.67 units on a scale — p=0.108

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
nPEP (non-invasive positive expiratory pressure) mask (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Duke University
Primary completion
Aug 2022

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Cough Severity as Measured by the Cough Visual Analog Scale (VAS)
-50.67 0.108
PRIMARY
Change in Quality of Life as Measured by the Cough-Specific Quality-of-Life Questionnaire (CQLQ)
-14.63 0.003 sig
PRIMARY
Change in Quality of Life as Measured by the Leicester Cough Questionnaire (LCQ)
2.53 0.025 sig
SECONDARY
Proximal Airway Reactance at 5 Hz (X5) as Assessed by Impulse Oscillometry
-3.19; -3.08

Summary

This study aims to determine if an expiratory resistance device that delivers non-invasive positive expiratory pressure (nPEP) will reduce or stop coughing, reduce airway resistance and improve quality of life in patients with tracheobronchomalacia (TBM) who are not candidates for tracheal stenting.

Eligibility Criteria

Inclusion Criteria

  • Age ≥18 years
  • Visualization of ≥50% collapse of the trachea or mainstem bronchus on CT scan or bronchoscopy
  • No upper or lower respiratory infection within 4 weeks
  • Having capacity to provide legal written informed consent

Exclusion Criteria

  • History of tracheobronchoplasty or chronic tracheal stenting
  • Current tracheostomy
  • History of external chest trauma
  • History of:
  • Active treatment for Lung cancer
  • Lung transplantation
  • Unstable congestive heart failure
  • History of spontaneous pneumothorax
  • Other medical conditions that interfere with participation in the study
  • Pregnant women
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04169282). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search